Sign In
Buy CRL
$232.51
-2.11 (-0.90%)
At Close: Jul 31, 2026
Ori Biotech and Charles River Laboratories Collaborate to Accelerate Life-Saving Cell and Gene Therapy Development and Manufacturing
08:30am, Wednesday, 18'th Sep 2024
New Biological Data Released from IRO® Cell Therapy Manufacturing Platform New Biological Data Released from IRO® Cell Therapy Manufacturing Platform
CRL Stock May Benefit From New Neuroscience Research Collaboration
10:30am, Monday, 09'th Sep 2024
Charles River's new alliance with Insightec to advance therapeutic development using focused ultrasound in neuroscience.
Why Is Charles River (CRL) Down 5.3% Since Last Earnings Report?
12:37pm, Friday, 06'th Sep 2024
Charles River (CRL) reported earnings 30 days ago. What's next for the stock?
SAN DIEGO, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Johnson Fistel, LLP (www.johnsonfistel.com), a shareholder rights law firm, announces its continuing investigation of whether certain directors and officer
Charles River Laboratories: Changing Economics Reduces Compounding Ability (Rating Downgrade)
06:31am, Thursday, 15'th Aug 2024
Charles River came in with another set of soft numbers, indicating a period of weaker business ahead for the company. Management is scaling back CapEx into the business and focusing on buybacks, sugge
NEW YORK, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Charles River Laboratories Inter
Why Charles River (CRL) International Revenue Trends Deserve Your Attention
10:21am, Monday, 12'th Aug 2024
Examine Charles River's (CRL) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.
Charles River Laboratories: Q2, Cost Structure Streamlining (Rating Upgrade)
09:00am, Saturday, 10'th Aug 2024
Weak biopharma market challenges persist, impacting CRL's revenue and bottom-line growth. Cost streamlining initiatives in place to generate $150 million in annualized cost savings by FY25. Growth pro
Charles River (CRL) Q2 Earnings Beat Estimates, 2024 View Down
02:30pm, Wednesday, 07'th Aug 2024
Charles River's (CRL) Manufacturing business segments report organic revenue growth, partially offset by lower revenues in the DSA and RMS segments.
Charles River Laboratories International Inc (CRL) Q2 2024 Earnings Call Transcript
02:21pm, Wednesday, 07'th Aug 2024
Charles River Laboratories International Inc (NYSE:CRL ) Q2 2024 Results Conference Call August 7, 2024 9:00 AM ET Company Participants Todd Spencer - Corporate Vice President of Investor Relations Ji
Charles River Labs Says It Expects Sales To Fall, Sending Its Stock Tumbling
01:31pm, Wednesday, 07'th Aug 2024
Shares of Charles River Laboratories (CRL) tumbled over 12% in intraday trading Wednesday after the company said it expects to post a decline in sales for the full fiscal year, instead of growth.
Here's What Key Metrics Tell Us About Charles River (CRL) Q2 Earnings
10:36am, Wednesday, 07'th Aug 2024
While the top- and bottom-line numbers for Charles River (CRL) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compa
Charles River Laboratories Stock Sinks As It Warns Of Continued Biotech Demand Slump, Lowers Forecast
10:06am, Wednesday, 07'th Aug 2024
Charles River Laboratories International Inc CRL reported second-quarter 2024 revenue of $1.03 billion on Wednesday, a decrease of 3.2% year over year, beating the consensus of $1.024 billion.
Charles River Laboratories (CRL) Surpasses Q2 Earnings and Revenue Estimates
09:11am, Wednesday, 07'th Aug 2024
Charles River Laboratories (CRL) came out with quarterly earnings of $2.80 per share, beating the Zacks Consensus Estimate of $2.39 per share. This compares to earnings of $2.69 per share a year ago.
Charles River cuts 2024 forecast as funding crunch among biotech clients persists
08:26am, Wednesday, 07'th Aug 2024
Charles River Laboratories trimmed its annual forecast on Thursday, as it no longer expects demand for its drug discovery and development services to improve in the second half of the year, sending it
